SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BMY (bristol myers squibb) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (154)10/25/2018 12:10:34 PM
From: DewDiligence_on_SI  Read Replies (2) | Respond to of 194
 
CC answer re Opdivo/NKTR-214 in NSCLC was not reassuring,



To: Miljenko Zuanic who wrote (154)10/29/2018 4:13:08 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 194
 
Enigmatic TMB comment by Roger Perlmutter on MRK’s 3Q18 CC:
I think that the question of how it is that mutation influences response rate, which it clearly does, is important to understand. People jump to the conclusion that that's neoepitopes and improved immune response. Not so clear for a whole variety of reasons.
Emphasis added.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News